Re: Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease
In this survey sent to the members of the Sexual Medicine Society of North American (SMSNA), Yafi et al. assessed the providers’ experience with intralesional injection of collagenase clostridium histolyticum (CCh) for Peyronie’s disease (PD). The anonymous, 33-question survey was sent to 693 members of SMSNA with valid email addresses and requested responses from CCh prescribers. The 100 responders (14.4% response rate), were relatively evenly distributed in their experience administering CCh injections with 36%, 23% and 41% of responders performing injections on ≤10 patients, 10–20 patients, and >20 patients respectively.